SSX2
SSX2 (SSX family member 2, also known as HOM-MEL-40, HD21 and CT5.2a) is a nuclear protein of the SSX family that may act as a modulator of transcription. It is best known for its involvement in synovial sarcoma translocations and its immune recognition in cancer patients. Browse Assay Genie's current range of SSX2 research reagents below, or read on for the biology behind the target.
SSX2 is a member of the synovial sarcoma X (SSX) breakpoint family of highly homologous proteins. UniProt annotates it as a protein that could act as a modulator of transcription, and the NCBI Gene summary notes that SSX proteins may function as transcriptional repressors. The protein localises to the nucleus, consistent with a role in regulating gene expression.
The SSX2 gene sits on the X chromosome, and HGNC places it in the SSX family and within the group of KRAB domain containing proteins. Alternative splicing of the gene produces multiple transcript variants. The gene also has an identical duplicate, GeneID 727837, located about 45 kb downstream in the opposite orientation on the X chromosome, which is worth bearing in mind when designing assays against the SSX2 gene or its transcripts.
The name reflects its disease history: SSX2 was originally described as synovial sarcoma, X breakpoint 2. Together with SSX1 and SSX4, the SSX2 gene is involved in the t(X;18)(p11.2;q11.2) translocation found characteristically in synovial sarcomas. This fuses the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes, and the resulting hybrid proteins are likely responsible for the transforming activity. SSX proteins can also elicit spontaneous humoral and cellular immune responses in cancer patients, which makes them potentially useful targets for cancer vaccine-based immunotherapy.
SSX2 is one of the SSX genes fused to the chromosome 18 translocation gene in the t(X;18) translocation found in synovial sarcomas.
SSX proteins elicit spontaneous humoral and cellular immune responses in cancer patients and are potential targets for vaccine-based immunotherapy.
SSX2 may act as a modulator of transcription, and SSX family proteins may function as transcriptional repressors.
The hybrid proteins formed by SSX gene fusions are likely responsible for transforming activity in synovial sarcoma.
UniProt describes SSX2 as a protein that could act as a modulator of transcription, and the NCBI Gene summary says SSX proteins may function as transcriptional repressors. It is found in the nucleus. Its fusion with the chromosome 18 synovial sarcoma translocation gene is linked to transforming activity.
SSX2 is the HGNC symbol for SSX family member 2, previously named synovial sarcoma, X breakpoint 2. Aliases include HOM-MEL-40, HD21, MGC3884, MGC15364, MGC119055, CT5.2a and SSX. UniProt lists the protein as Protein SSX2. Alternative splicing gives multiple transcript variants.
SSX2, with SSX1 and SSX4, can be fused to the synovial sarcoma translocation gene in the t(X;18)(p11.2;q11.2) translocation found in synovial sarcomas. SSX proteins also trigger immune responses in cancer patients, so they are considered potential cancer vaccine targets.
Related SSX2 pathway partners and cancer-associated targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q16385; product specifications from Assay Genie datasheets.